Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Introducing a translationally relevant mouse model of radiosurgery-induced unilateral hearing loss.

Frontiers in neuroscience·2026
Same author

[Innovation in the radiotherapy management of vestibular schwannomas].

Revue medicale suisse·2026
Same author

Altered parietal multisensory integration in chronic tinnitus during closed-loop real-time fMRI auditory downregulation.

NeuroImage. Clinical·2026
Same author

Plasma Proteome Profiling of Centenarian Across Switzerland Reveals Key Youth-Associated Proteins.

Aging cell·2026
Same author

Vestibular dose predicts toxicity in stereotactic radiosurgery for vestibular schwannomas.

Clinical and translational radiation oncology·2026
Same author

A randomized clinical trial of peritonsillar abscess treatment comparing drainage and tonsillectomy.

American journal of otolaryngology·2025

Related Experiment Video

Updated: Mar 31, 2026

Canalostomy As a Surgical Approach to Local Drug Delivery into the Inner Ears of Adult and Neonatal Mice
09:34

Canalostomy As a Surgical Approach to Local Drug Delivery into the Inner Ears of Adult and Neonatal Mice

Published on: May 25, 2018

11.9K

NOX3-TARGETED THERAPIES FOR INNER EAR PATHOLOGIES.

Francis Rousset1, Stephanie Carnesecchi, Pascal Senn

  • 1Department of Pathology and Immunology, Centre Médical Universitaire, 1, rue Michel-Servet CH-1211 Geneva 4, Switzerland. Francis.Rousset@unige.ch.

Current Pharmaceutical Design
|October 30, 2015
PubMed
Summary

Reactive oxygen species (ROS) contribute to inner ear diseases. The NOX3 enzyme is implicated, and targeting it may offer new therapies for hearing loss and other pathologies.

More Related Videos

Posterior Semicircular Canal Approach for Inner Ear Gene Delivery in Neonatal Mouse
03:52

Posterior Semicircular Canal Approach for Inner Ear Gene Delivery in Neonatal Mouse

Published on: March 2, 2018

11.1K
A Comparative Study of Drug Delivery Methods Targeted to the Mouse Inner Ear: Bullostomy Versus Transtympanic Injection
09:18

A Comparative Study of Drug Delivery Methods Targeted to the Mouse Inner Ear: Bullostomy Versus Transtympanic Injection

Published on: March 8, 2017

14.2K

Related Experiment Videos

Last Updated: Mar 31, 2026

Canalostomy As a Surgical Approach to Local Drug Delivery into the Inner Ears of Adult and Neonatal Mice
09:34

Canalostomy As a Surgical Approach to Local Drug Delivery into the Inner Ears of Adult and Neonatal Mice

Published on: May 25, 2018

11.9K
Posterior Semicircular Canal Approach for Inner Ear Gene Delivery in Neonatal Mouse
03:52

Posterior Semicircular Canal Approach for Inner Ear Gene Delivery in Neonatal Mouse

Published on: March 2, 2018

11.1K
A Comparative Study of Drug Delivery Methods Targeted to the Mouse Inner Ear: Bullostomy Versus Transtympanic Injection
09:18

A Comparative Study of Drug Delivery Methods Targeted to the Mouse Inner Ear: Bullostomy Versus Transtympanic Injection

Published on: March 8, 2017

14.2K

Area of Science:

  • Oto-rhino-laryngology
  • Molecular Biology
  • Biochemistry

Background:

  • Inner ear pathologies significantly impact patient morbidity and quality of life.
  • Reactive oxygen species (ROS) are increasingly recognized as key pathological mediators in these conditions.
  • NADPH oxidase (NOX) enzymes, particularly NOX3, are emerging as critical players in inner ear ROS production.

Purpose of the Study:

  • To review the evidence implicating NOX3 in inner ear pathologies.
  • To discuss the therapeutic potential of targeting NOX3 activity.
  • To highlight the need for specific NOX3 inhibitors for inner ear treatment.

Main Methods:

  • Review of existing literature on NOX3 function and inner ear diseases.
  • Analysis of studies involving NOX3 mutant mice and therapeutic interventions.
  • Discussion of pharmacological and molecular strategies for NOX3 inhibition.

Main Results:

  • NOX3 is highly expressed in both vestibular and cochlear compartments of the inner ear.
  • NOX3 mutations affect vestibular function, while NOX3 activation contributes to drug-, noise-, and age-related hearing loss.
  • Non-specific NOX inhibitors and antioxidants show promise in animal models, indicating therapeutic potential.

Conclusions:

  • NOX3 is a significant contributor to inner ear pathologies, including hearing loss.
  • Targeting NOX3 offers a promising therapeutic avenue for preventing and treating inner ear disorders.
  • Development of specific NOX3 inhibitors is crucial for effective redox-targeted therapies.